Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

Yarilina, 2012, Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors., Arthritis Rheum, 64, 3856, 10.1002/art.37691

Fridman, 2011, Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation., J Invest Dermatol, 131, 1838, 10.1038/jid.2011.140

Caocci, Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis [published online ahead of print August 9, 2013]., Leukemia

Wysham, 2013, An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor., Chest, 143, 1478, 10.1378/chest.12-1604

Goldberg, 2013, Bilateral toxoplasmosis retinitis associated with ruxolitinib., N Engl J Med, 369, 681, 10.1056/NEJMc1302895

Colomba, 2012, Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report., BMC Res Notes, 5, 552, 10.1186/1756-0500-5-552

Wathes, 2013, Progressive multifocal leukoencephalopathy associated with ruxolitinib., N Engl J Med, 369, 197, 10.1056/NEJMc1302135

Verstovsek, 2010, Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis., N Engl J Med, 363, 1117, 10.1056/NEJMoa1002028

Heine, 2013, The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo., Blood, 122, 1192, 10.1182/blood-2013-03-484642